There are 2789 resources available
LBA54 - Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): Results of the randomized phase II INTEGA trial (AIO STO 0217)
Presenter: Alexander Stein
Session: Mini oral session - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
LBA55 - Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen
Presenter: Eric Van Cutsem
Session: Mini oral session - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
1373MO - JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Rui-Hua Xu
Session: Mini oral session - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
LBA10 - Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer: Final results of the NIFE-trial (AIO-YMO HEP-0315), a randomized phase II study of the AIO biliary tract cancer group
Presenter: Lukas Perkhofer
Session: Mini oral session - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
LBA37 - IMMUTACE: A biomarker-orientated, multi center phase II AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC)
Presenter: Arndt Vogel
Session: Mini oral session - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
965MO - GTB-3550 tri-specific killer engager safely activates and delivers IL-15 to NK cells, but not T-cells, in immune suppressed patients with advanced myeloid malignancies, a novel paradigm exportable to solid tumors expressing Her2 or B7H3
Presenter: Jeffrey Miller
Session: Mini oral session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
862MO - Gene expression profile differentiates short-term and long-term survivors with immunotherapy in patients with recurrent/metastatic head and neck cancer
Presenter: Loris De Cecco
Session: Mini oral session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast
863MO - Nomogram for predicting survival for patients receiving definitive chemoradiation in locally advanced squamous cell carcinoma of the head and neck: A secondary analysis of NRG/RTOG 0129, 0522, and 1016
Presenter: Michael Kharouta
Session: Mini oral session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast
864MO - Role of geriatric assessment in tailoring treatment of locally advanced head and neck cancer: The ELDERLY study
Presenter: Paolo Bossi
Session: Mini oral session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast
865MO - RMAC study: A randomized study evaluating the efficacy of metronomic adjuvant chemotherapy in patients with recurrent head and neck cancers post salvage surgery, not eligible for re-irradiation
Presenter: Nandini Menon
Session: Mini oral session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast